Navigation Links
Pulmonary Drug Delivery Devices Market to Reach US$43.05 Billion by 2024: Rising Prevalence of Respiratory Disorders to Drive Growth, Notes TMR
Date:2/9/2017

ALBANY, New York, February 9, 2017 /PRNewswire/ --

The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc. states a new research report by Transparency Market Research. With the top five players accounting for more than 67%, the market exhibits a largely consolidated structure.

Analysts project this market to remain competitive over the forthcoming years, specifically the drug markets for asthma and chronic obstructive pulmonary diseases (COPD), thanks to the robust product pipelines of established drug-makers.

According to the research report, the worldwide market for pulmonary drug delivery devices, which stood at US$32.2 bn in 2015, is expected to progress at a CAGR of 3.30% between 2016 and 2024 and reach US$43.05 bn by the end of the forecast period. The application of these devices is higher in the asthma segment and is expected to remain so over the next few years, thanks to the robust pipeline of drugs for the treatment of asthma.

Download PDF Brochure of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=873

North America to Continue to Lead Global Market 

An analysis of the geographical presence of the global pulmonary drug delivery devices market has also been presented in this research report. As per the study, Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa are the prime regional markets for pulmonary drug delivery devices. North America, among these, is leading the global market with Europe trailing closely. The key factor behind the rise of both the regional markets is the increasing prevalence of COPD.

With the technological advancements in pulmonary drug delivery devices, North America is likely to retain its position across the world with a share of more than 40% by the end of the forecast period. The markets for pulmonary drug delivery devices in Asia Pacific, Latin America, and the Middle East and Africa are also projected to witness significant growth in the next few years, owing to the increasing prevalence of respiratory disorders. The rising level of awareness among consumers regarding health and wellness and the increase in the disposable income are also anticipated to propel these markets in the near future, states the research report.

Rising Pool of Respiratory Disorder Patients to Fuel Market's Growth 

"The rising pool of patients suffering from respiratory disorders is having the most prominent impact on the global market for pulmonary drug delivery devices," states an analyst at TMR. The alarming rise in air pollution and the increasing number of smokers, worldwide, are adding substantially to the already worsened situation of COPD patient pool, leading to a remarkable surge in the demand for these devices. Analysts expect this scenario to remain so over the period of forecast, resulting in a high demand pace for these devices.

In addition to this, the market is anticipated to benefit from the increasing research and development in the treatments for asthma and COPD in the near future. However, the imminent patent expiry of blockbuster drugs and several regulatory hurdles may limit the growth of this market to some extent in the years to come, notes the research study.

Inquire for Report Customization: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=873

The study presented here is based on a report by Transparency Market Research (TMR) titled "Pulmonary Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 - 2024."

The global pulmonary drug delivery devices market has been segmented as follows:

By Product type 

  • Dry Powder Inhalers
    • Single-dose inhalers
    • Multi-dose inhalers
  • Metered Dose Inhalers
    • Manually-actuated pressurized inhaler
    • Breath-actuated pressurized inhaler
  • Nebulizers
    • Jet nebulizers
    • Ultrasonic wave nebulizers
    • Vibrating mesh nebulizers

By Application 

  • Asthma
  • COPD
  • Cystic Fibrosis
  • Others

By Distribution Channel 

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce

By Geography 

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Browse Related Research Report: 

Pulmonary Drugs Market (Drug Class - Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), Antihistamines, Vasodilators, Short-Acting Beta2-Agonists (SABA), Anticholinergics, Combination Drugs, MAbs, Enzymes, Antibiotics, and Antileukotrienes; Application - Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, and Cystic Fibrosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

http://www.transparencymarketresearch.com/pulmonary-drugs-market.html

Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

http://www.transparencymarketresearch.com/scleroderma-diagnostics-therapeutics.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Blog: http://www.tmrblog.com/


'/>"/>
SOURCE Transparency Market Research
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute
2. Site-Specific Drug Delivery Market, By Application (Pulmonary, Ocular, Oncology, CNS, Cardiovascular) - World Forecasts to 2022
3. Pulmonary Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
4. Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
5. Global Idiopathic Pulmonary Fibrosis Drugs Price Strategies Report 2016: How the Price Advanced from 2012 and Forecast to 2021 - Research and Markets
6. DS Biopharma Announces DS102 will be Developed for Pulmonary Disorders in Addition to NASH
7. Bayer to Present Pulmonary Hypertension Data at American Thoracic Society (ATS) 2016 International Conference
8. Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias
9. Pipeline of Pulmonary Arterial Hypertension Market (PAH) Reviewed for H1 2016 in New Report
10. Frontier Pharma Report: Chronic Obstructive Pulmonary Disease (COPD) Market - Which Molecular Targets Appear Most Frequently in the Pipeline? - Research and Markets
11. Pulmatrixs iSPERSE Inhaled Drug Delivery Technology Offers Hope to Patients with Pulmonary Lung Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
Breaking Medicine News(10 mins):